LexaGene Starts the Year with Additional MiQLab Sales
January 03 2022 - 7:45AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
has commercialized an instrument for automated multiplex PCR
testing, is pleased to announce three additional purchase orders
for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota,
and New York.
Julie Griggs, LexaGene’s Global Director of Sales, stated, “My
team is diligently engaged with numerous veterinary practices, both
private and corporate. Many of the veterinarians we have spoken to
share our excitement over the value of in-clinic PCR testing and
the capabilities that the MiQLab System can provide to their
practices. It is gratifying to welcome 2022 with a strong start and
continue our momentum as we work on closing additional sales.”
Dr. Jack Regan, LexaGene’s Founder and CEO said, “I’m pleased
that we are making headway in the veterinary diagnostics
marketplace. By acquiring MiQLab Systems, veterinary practices are
setting themselves apart from their competition, as this technology
allows them to elevate the standard of care they provide to
companion animals. We look forward to educating veterinary
practices in the coming year, regarding the importance of in-clinic
PCR testing, and aim to revolutionize veterinary diagnostics
through the sale of MiQLab Systems. No longer should veterinary
practices empirically diagnosis our companion animals or send
samples off to labs only to wait days or weeks for results when
they can have a treatment plan in a fraction of the time.”
LexaGene is participating in the upcoming Veterinary Meeting and
Expo (VMX) in Orlando, Florida, where more than 6,500
veterinarians, veterinary technicians, and practice managers will
gather mid-January. On Sunday, January 16th, Dr. Jack Regan will be
a presenter at the conference. Participants can attend his
presentation entitled, “In-Clinic PCR Testing for Pathogen and
Resistance Detection,” at 9:00 a.m. in the VMX Learning
Theater.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings, Inc.LexaGene develops
molecular diagnostic systems for pathogen detection and genetic
testing for other molecular markers for on-site rapid testing in
veterinary diagnostics, food safety and for use in open-access
markets such as clinical research, agricultural testing, and
biodefense. End-users simply need to collect a sample, load it onto
the instrument with a sample preparation cartridge, enter sample ID
and press ‘go’. The MiQLab™ system delivers excellent sensitivity,
specificity, and breadth of detection and can return results in
approximately two hours. The unique open-access feature is designed
for custom testing so that end-users can load their own real-time
PCR assays onto the instrument to target any genetic target of
interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director, Marketing
gwinslow@lexagene.com
978.482.6237
Investors:
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024